Lv11
50 积分 2023-08-31 加入
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
8小时前
待确认
Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy
7天前
已完结
A method for tumor dosimetry based on hybrid planar‐SPECT/CT images and semiautomatic segmentation
24天前
已完结
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
27天前
已关闭
Novel 64Cu-labeled Trimeric PSMA Ligand Unequivocally Identifies Local Recurrence of Prostate Cancer Ambiguously Imaged by 18F-DCFPyL PSMA PET/CT
1个月前
已完结
Molecular recognition of fibroblast activation protein for diagnostic and therapeutic applications
1个月前
已完结
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
2个月前
已完结
FAP-Targeted Radionuclide Therapy of Advanced Radioiodine-Refractory Differentiated Thyroid Cancer With Multiple Cycles of 177Lu-FAPI-46
2个月前
已完结
FAP-targeted radionuclide therapy with [177Lu]Lu-FAPI-46 in metastatic nasopharyngeal carcinoma
2个月前
已完结
Feasibility and Therapeutic Potential of 177Lu–Fibroblast Activation Protein Inhibitor–46 for Patients With Relapsed or Refractory Cancers
2个月前
已完结
皖公网安备34019202002308
